Rationale documents for antifungal agents

Rationale documents for antifungal agents.

Template for producing a Rationale Document (26 June 2014)

• Amphotericin B v 2.0 (2020)
• Anidulafungin vs. Candida v 3.0 (2020) 

• Caspofungin vs Candida - there is no caspofungin RD and no specific caspofungin breakpoints. Use  anidulafungin and micafungin as markers for caspofungin susceptibility where isolates "S" to  both anidulafungin and micafungin are considered susceptible to caspofungin. Similarly, for C. parapsilosis isolates "I" for anidulafungin and micafungin then can be reported "I" for caspofungin.

• Fluconazole vs. Candida v 3.0 (2020) 
• Isavuconazole vs. Aspergillus v 2.0 (2020) 
• Itraconazole v 3.0 (2021)
• Micafungin vs. Candida v 2.0 (2020) 
• Posaconazole v 3.0 (2020) 
• Rezafungin v 1.0 (2024)
• Voriconazole v 4.0 (2020)  

Archived rationale documents:

• Amphotericin B vs. Candida v 1.0
• Amphotericin B vs. Aspergillus v 1.0
• Anidulafungin vs. Candida  v 2.0 (comments during consultation)
• Fluconazole vs. Candida v 2.0 (comments during consultation) - 2018
• Isavuconazole vs. Aspergillus v 1.0
• Itraconazole vs. Aspergillus v 1.1 (comments during consultation)
• Micafungin vs. Candida v 1.0 (comments during consultation)
• Posaconazole v 2.0 (this document constitutes a merge and update of previous individual documents: Posaconazole vs. Candida v 1.0 and Posaconazole vs. Aspergillus v 1.0).
• Voriconazole v 3.0 (19 Dec 2017) (this constitutes a merge and update of previous individual documents: Voriconazole vs. Candida v 2.0 and Voriconazole vs. Aspergillus v 1.0).
• Itraconazole vs. Aspergillus v 2.0 (2020) and Itraconazole vs. Candida v 1.0 - amalgamated 2021 in RD itraconazole v 3.0